Amedisys, Inc.

As of August 14, 2025, Amedisys, Inc. is considered very expensive with a P/E ratio of 20, higher than its peers and industry averages, and has underperformed the S&P 500 significantly, indicating it may be overvalued despite a low PEG ratio of 0.30.

As of May 8, 2025, Amedisys, Inc. is considered overvalued with a P/E ratio of 20.53, significantly higher than its peers, despite recent stock performance outpacing the S&P 500, while facing a concerning long-term decline of 50.66% over five years.

As of June 10, 2025, Amedisys, Inc. shows a bullish trend supported by weekly MACD and Bollinger Bands, though caution is advised due to a bearish monthly KST.

As of March 2022, Amedisys, Inc.'s management team includes Paul Kusserow (Chairman, President, CEO), Richard Lechleiter (Lead Independent Director), and several Independent Directors: Ivanetta Samuels, Vickie Capps, Molly Coye, and Julie Klapstein. They are responsible for the company's strategic direction and governance.

Amedisys, Inc. is a healthcare services company that provides home health, hospice, and personal care services, with a recent net sales of $595 million and a market cap of approximately $3.69 billion. Key financial metrics include a P/E ratio of 20.00 and a return on equity of 15.00%.

As of Jun 18, Amedisys, Inc. has a market capitalization of $3.69 billion, with net sales of $2.37 billion and a net profit of $85.38 million over the last four quarters.